Compositions and methods of modulating short-chain dehydrogenase activity

Abstract

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

1 .- 27 . (canceled) 
     
     
         28 . A composition for topical administration comprising: sodium cromoglicate, an amphoteric surfactant, and an alkoxylated cetyl alcohol, wherein the total amount of a preservative present in the composition is about 0.2% w/w or less. 
     
     
         29 . The composition according to  claim 28 , wherein the total amount of preservative is selected from
 a) about 0.001% to about 0.2% w/w of the composition,   b) about 0.01% to about 0.15% w/w of the composition, or   c) about 0.1% w/w of the composition.   
     
     
         30 . The composition according to  claim 28 , wherein the preservative, if present, is not one or more of benzyl alcohol and triclosan. 
     
     
         31 . The composition according to  claim 28 , wherein the preservative is chlorocresol. 
     
     
         32 . The composition according to  claim 28 , wherein the amphoteric surfactant is a balanced amphoteric surfactant. 
     
     
         33 . The composition according to  claim 28 , wherein the alkoxylated cetyl alcohol is polypropoxylated cetyl alcohol. 
     
     
         34 . The composition according to  claim 28 , wherein the amphoteric surfactant comprises disodium cocoamphodiacetate. 
     
     
         35 . The composition according to  claim 28 , further comprising a corticosteroid. 
     
     
         36 . The composition according to  claim 28 , wherein the composition comprises an aqueous phase and an oil phase. 
     
     
         37 . The composition according to  claim 36 , wherein the composition is an oil-in-water emulsion. 
     
     
         38 . The composition according to  claim 28 , wherein the composition is a foam, a cream, an ointment, or a lotion. 
     
     
         39 . The composition according to  claim 28 , packaged in a tube, tub, bottle, or pressurized aerosol container. 
     
     
         40 . A method for treating a skin disease or condition comprising administering the composition according to  claim 28 . 
     
     
         41 . The method according to  claim 40 , wherein the skin disease or condition comprises one or more of skin mast cells, delayed (cellular) hypersensitivity reactions, and inflammation. 
     
     
         42 . The method according to  claim 40 , wherein the skin disease or condition is selected from atopic dermatitis, eczema, contact sensitivity, psoriasis, drug sensitivity reactions, aphthous ulcers, pemphigus, urticaria, urticaria pigmentosa, pyoderma gangrenosum, skin ulcers associated with Crohn's disease, burns, insect stings/bites, morphoea (circumscribed or localised scleroderma), and sunburn. 
     
     
         43 . The method according to  claim 40 , further comprising administering a corticosteroid. 
     
     
         44 . The method according to  claim 43 , wherein the corticosteroid is incorporated into the composition or administered as a separate composition. 
     
     
         45 . A composition for topical administration comprising:
 a) sodium cromoglicate;   b) an amphoteric surfactant;   c) an alkoxylated cetyl alcohol, and   d) a preservative in an amount selected from
 i) about 0.001% to about 0.2% w/w of the composition, 
 ii) about 0.01% to about 0.15% w/w of the composition, or 
 iii) about 0.1% w/w of the composition. 
   
     
     
         46 . The composition of  claim 45 , wherein the amphoteric surfactant comprises disodium cocoamphodiacetate; the alkoxylated cetyl alcohol is polypropoxylated cetyl alcohol; and the preservative is chlorocresol. 
     
     
         47 . The composition of  claim 45 , further comprising a corticosteroid.